TrialThoracic cancer2022

Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial.

Juan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.